Global Metagenomic Sequencing Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (undefined)

Global Metagenomic Sequencing Market is Segmented By Technology (Sequencing, Bioinformatics, PCR, Microarray, and Others), By Product (Instruments, Reagents & Consumables, Services, and Analysis Softwares), By Application (Drug Discovery, Disease Diagnosis, Environmental Remediation, Gut Microbe Characterization, and Others), By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Agriculture & Biofuel Companies, Hospitals & Clinics, and Others), By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The report offers the value (in USD billion) for the above-mentioned segments.

Global Metagenomic Sequencing Market Size

Market Size in USD


Study Period2023 - 2030
Base Year of Estimation2022
Fastest Growing MarketAsia Pacific
Largest MarketNorth America
Market ConcentrationHigh
Major PlayersIllumina, QIAGEN, Thermo Fisher Scientific, Oxford Nanopore Technologies, BGI Group
*Disclaimer: Major players are listed in no particular order.
*Source: Coherent Market Insights
Want to purchase customized report?
please let us know !

Global Metagenomic Sequencing Market Analysis

Global metagenomic sequencing market size is expected to reach US$ 4.39 Bn by 2030, from US$ 1.41 Bn in 2023, exhibiting a compound annual growth rate (CAGR) of 17.6% during the forecast period. Metagenomic sequencing refers to the direct genetic analysis of genomes that are contained within an environmental sample. It involves the study of genetic material recovered from environmental samples such as water or soil directly, without the need for culturing individual species. The technique provides a powerful tool to assess the biodiversity of microbial communities and understand their role in ecosystems. Metagenomic sequencing allows researchers to access and study the vast majority of microbes that cannot be cultured in a lab. It helps in identifying novel genes, enzymes, and natural products which have diverse applications in biotechnology, agriculture, medicine, renewable energy, bioremediation and more. The growth of the market is due to the decreasing costs of sequencing, advancements in sequencing technologies, growing genomics research, and rising government and private funding for metagenomics research.

The metagenomic sequencing market is segmented into technology, product, application, end user and region. By technology, the market is segmented into sequencing, bioinformatics, PCR, microarray, and others. The sequencing segment accounted for the largest share in 2022. The growth of this segment is due  to the continuously declining costs of sequencing and technological improvements in Next-generation Sequencing (NGS) platforms.

Global Metagenomic Sequencing Market Drivers

  • Decreasing sequencing costs: The cost of sequencing has declined substantially over the past decade, thus making metagenomic sequencing more accessible to a wider range of researchers and end users. The cost of sequencing a human genome was over US$ 100 million in 2001. This has  reduced to around US$600-1000 per genome with the advent of next-generation sequencing technologies by companies like Illumina, a biotechnology company, Oxford Nanopore, and others. Similarly, the cost per Mb of microbial sequencing has also fallen exponentially from thousands to just a few dollars. This is expanding the adoption of metagenomic sequencing in research and clinical applications. Continued improvements in sequencing chemistries, instruments, miniaturization, and nanotechnologies will further lower the costs and support the growth of the metagenomic sequencing market.
  • Technological advancements in sequencing platforms: New and advanced high-throughput next generation sequencing (NGS) platforms are being developed and launched by companies. These provide higher accuracy, faster turn-around times, longer read lengths, and ability to sequence more samples in a single run. For instance, in September 2020, Oxford Nanopore Technologies, a UK-based company launched the PromethION 2 Solo for nanopore-based long read sequencing. It offers on-demand access to 48 flow cells and increased throughput. Similarly, Illumina launched NovaSeq X Series sequencers that can produce 6Tb of data in less than two days. Such advanced sequencing systems are driving the adoption of metagenomics in various research and clinical fields.
  • Growth of metagenomics research: Metagenomics research to analyze microbial communities has gained significant interest over the past decade. The number of metagenomics studies published has grown exponentially from less than 100 in 2007 to over 2000 in 2019 as per the National Center for Biotechnology Information (NCBI) database. Moreover, large-scale metagenomics projects like the Earth BioGenome Project, MetaSUB, and the human microbiome project have been established in recent years. This growing research is supported by declining costs, improved databases and increasing applications across healthcare, biotechnology, agriculture, and other fields.
  • Government and private funding: Substantial government and private funding is being provided globally to support metagenomics research initiatives and projects. For instance, the U.S. government announced US$ 515 million funding for the Human Microbiome Project in 2019. Similarly, MetaSUB, an international organization, received US$ 5 million in funding from Genome Canada and Ontario Genomics for microbiome sequencing of global cities. Likewise, private entities like the Gates Foundation, Wellcome Trust, and Simons Foundation provide huge research grants for metagenomics studies. This availability of research funding will propel market growth.

Global Metagenomic Sequencing Market Opportunities

  • Synthetic biology and genetic engineering: Metagenomics is uncovering novel enzymes, bioactives, and pathways in microbes that have huge potential for synthetic biology and metabolic engineering applications. The companies are mining metagenomic sequence data to identify novel antimicrobials, biopolymers, biosurfactants, biocatalysts and others which can be heterologously expressed and commercially produced via synthetic biology approaches. For instance, in June 2021, Ginkgo Bioworks, a biotech company, leveraged metagenomics to produce novel cannabinoids. Such applications create significant opportunities for market growth.
  • Agri-biotechnology: Metagenomics is enabling identification of plant growth promoting microbes, biocontrol agents, microbial inoculants and others that can transform agricultural productivity in a sustainable manner. The companies like AgBiome, Indigo, and others are leveraging metagenomics for bioprospecting of agricultural microbiomes and developing microbial crop protection and growth enhancement products. The agri-biotech applications of metagenomics will spur its adoption in the near future.
  • Bioremediation: Metagenomics allows rapid assessment of microbial communities at contaminated sites and aids in bioaugmentation or biostimulation-based bioremediation approaches. It helps monitor changes during bioremediation and identify novel degrading microbes and catabolic genes. Metagenomics analysis is being widely used for bioremediation of soils that are contaminated with hydrocarbons, heavy metals, dyes, and others. The central role of metagenomics in environmental biotechnology creates significant opportunities.
  • Single cell metagenomics: Single cell sequencing technologies are enabling metagenomics at the resolution of individual cells, revealing extensive heterogeneity even within the same species. Single cell metagenomics provides finer taxonomic classification, improves detection of rare taxa, and enables genome reconstruction. For instance, in March 2022, 10x Genomics, Biotechnology Company offers single cell metagenomics workflows that can profile thousands of uncultured microbes in parallel. Single cell metagenomics provides new insights and will be a fast-growing opportunity area.

Global Metagenomic Sequencing Market Restraints

  • Complexity of data analysis: Metagenomic analysis involves bioinformatically intensive workflows for quality control, taxonomic classification, functional annotation, comparative analysis, and others. Lack of complete reference databases also hampers analysis. Multi-omics integration poses additional challenges. Expertise in microbiology, statistics and computation biology is required for deriving meaningful insights. This complexity limits wider adoption.

Counterbalance: complete reference databases should be made available by the market players to make correct analysis of the same.

  • Need for standardized protocols: The lack of standardized protocols for sample collection, metadata recording, DNA/RNA extraction, library prep, and data analysis affects inter-study comparability. Variations in these steps can bias results. Establishing robust experimental and analytical standards is essential for high-quality metagenomics studies and translation into clinical applications.
  • Ethical and legal concerns: Metagenomic analysis of human samples raises privacy concerns due to potential extraction of host Deoxyribonucleic Acid (DNA). Accessibility of human microbiome data requires careful handling as per regulations like Health Insurance Portability and Accountability Act (HIPAA). Environmental metagenomic mining for commercial use also raises issues like benefit sharing, prior informed consent, and others  Addressing these ethical and legal issues is important for the field.

Analyst’s View on Global Metagenomic Sequencing Market:

Global metagenomic sequencing market is expected to witness steady growth over the forecast period due to increased adoption of workforce management software and cloud-based platforms. It present an opportunity for stakeholders to optimize resource planning and allocation on a real-time basis and the rising demand for nurses caused by aging populations worldwide and increasing prevalence of chronic diseases. Developed markets in North America and Western Europe dominate due to higher allocation of resources to the healthcare sector compared to other regions